Trials / Completed
CompletedNCT03903549
Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers
A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Five Eleven Pharma, Inc. · Industry
- Sex
- All
- Age
- 45 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
This study investigates the initial safety profile of \[18F\]P17-059 in healthy volunteers including dosimetry determination, and compares regional brain uptake and kinetics of \[18F\]P17-059 in Parkinson's disease patients with regional brain uptake and kinetics of \[18F\]P17-059 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]P17-059 | Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning |
Timeline
- Start date
- 2022-07-15
- Primary completion
- 2022-12-19
- Completion
- 2022-12-19
- First posted
- 2019-04-04
- Last updated
- 2023-01-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03903549. Inclusion in this directory is not an endorsement.